The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Biomarkers of response and resistance to antiangiogenic therapy
Open accessAbstract
No validated biological markers (or biomarkers) currently exist for appropriately selecting patients with cancer for antiangiogenic therapy. Nor are there biomarkers identifying escape pathways that should be targeted after tumors develop resistance to a given antiangiogenic agent. A number of potential systemic, circulating, tissue and imaging biomarkers have emerged from recently completed phase I-III studies. Some of these are measured at baseline (for example VEGF polymorphisms), others are measured during treatment (such as hypertension, MRI-measured K(trans), circulating angiogenic molecules or collagen IV), and all are mechanistically based. Some of these biomarkers might be pharmacodynamic (for example, increase in circulating VEGF, placental growth factor) while others have potential for predicting clinical benefit or identifying the escape pathways (for example, stromal-cell-derived factor 1alpha, interleukin-6). Most biomarkers are disease and/or agent specific and all of them need to be validated prospectively. We discuss the current challenges in establishing biomarkers of antiangiogenic therapy, define systemic, circulating, tissue and imaging biomarkers and their advantages and disadvantages, and comment on the future opportunities for validating biomarkers of antiangiogenic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“no validated biomarkers are available to guide the use of antiangiogenic drugs7,126.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Cited by
Sorted by citations
Items 401–500 of 573
Yunus, M., Jansson, P. J., Kovačević, Ž., Kalinowski, D. S., & Richardson, D. R. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.04.017 · Cited by 11
Klein, S., & Duda, D. G. (2021) · Cancers · doi:10.3390/cancers13194919 · Cited by 10
Self-citationQi, L., Du, J., Zhang, Z., Diao, L., Chen, X., & Yao, X. (2013) · British Journal of Urology · doi:10.1111/bju.12191 · Cited by 10
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumours
Dey, N., De, P. K. R., & Leyland-Jones, B. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.439 · Cited by 74
Chamseddine, S., Mohamed, Y. I., Lee, S. S., Yao, J. C., Hu, Z. I., Cao, H. S. T., Xiao, L., Sun, R., Morris, J. S., Hatia, R. I., et al. (2023) · Oncology · doi:10.1159/000531870 · Cited by 9
Self-citationPhase I study of pazopanib plus TH-302 in advanced solid tumors
Riedel, R. F., Meadows, K. L., Lee, P. H., Morse, M. A., Uronis, H. E., Blobe, G. C., George, D. J., Crawford, J., Niedzwiecki, D., Rushing, C. N., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3256-2 · Cited by 9
Optimal duration of systemic treatment in metastatic colorectal cancer
Simkens, L. H. J., Koopman, M., & Punt, C. J. A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000087 · Cited by 9
Díaz‐Rubio, E., Pietrantonio, F., & de Braud, F. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0075 · Cited by 9
Exploring the role of endothelium in the tumour response to anti-angiogenic therapy
He, M. Y., Halford, M. M., Achen, M. G., & Stacker, S. A. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140173 · Cited by 9
Identification of specifically activated angiogenic molecules in HMGB-1-induced angiogenesis
Kim, W. K., Kwon, Y., Park, M., Yun, S., Kwon, J., & Kim, H. (2017) · BMB Reports · doi:10.5483/bmbrep.2017.50.11.129 · Cited by 9
Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy
de Groot, J., Reardon, D. A., & Batchelor, T. T. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e71 · Cited by 11
Self-citationGatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Maggio, I., Tonon, C., Lodi, R., Agati, R., Bartolini, S., & Brandes, A. A. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4604 · Cited by 9
The Role of Angiogenesis in Cancer
Taylor, M., Coleman, R. L., & Sood, A. K. (2015) · doi:10.1002/9781118468678.ch6 · Cited by 9
Zabel, W. J., Allam, N., Foltz, W. D., Flueraru, C., Taylor, E., & Vitkin, I. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07000-1 · Cited by 8
Wu, Q., Arnheim, A. D., & Finley, S. D. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0243 · Cited by 8
The role of PET in imaging of the tumour microenvironment and response to immunotherapy
Lilburn, D. M. L., & Groves, A. M. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.08.004 · Cited by 8
Li, J., Cheng, Y., Bai, C., Xu, J., Shen, L., Li, J., Zhou, Z., Li, Z., Chi, Y., Yu, X., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100453 · Cited by 8
Fornaro, L., Musettini, G., Orlandi, P., Pecora, I., Vivaldi, C., Banchi, M., Salani, F., Fini, E., Massa, V., Catanese, S., et al. (2022) · PubMed Central · Cited by 8
Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key
Drzał, A., Dziurman, G., Hoła, P., Lechowski, J., Delalande, A., Swakoń, J., Pichon, C., & Elas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512156 · Cited by 8
Halford, M. M., Tebbutt, N. C., Desai, J., Achen, M. G., & Stacker, S. A. (2012) · Colorectal Cancer · doi:10.2217/crc.12.9 · Cited by 8
Assessment of tumor response to tyrosine kinase inhibitors
Lowery, A. R. (2011) · Frontiers in bioscience · doi:10.2741/3836 · Cited by 8
Crosstalk between Stem and Progenitor Cellular Mediators with Special Emphasis on Vasculogenesis
Rohban, R., Prietl, B., & Pieber, T. R. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000477677 · Cited by 9
Lee, S., Muralidharan, V., Tebbutt, N. C., Wong, P., Fang, C., Liu, Z.-M., Gan, H. K., Sachinidis, J. I., Pathmaraj, K., Christophi, C., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05074-5 · Cited by 8
Multi-model quantitative MRI of uterine cancers in precision medicine’s era—a narrative review
Gennarini, M., Canese, R., Capuani, S., Miceli, V., Tomao, F., Palaia, I., Zecca, V., Maiuro, A., Balba, I., Catalano, C., et al. (2025) · Insights into Imaging · doi:10.1186/s13244-025-01965-z · Cited by 7
Applegate, C. C., Lowerison, M. R., Hambley, E., Song, P., Wallig, M. A., & Erdman, J. W. (2021) · Scientific Reports · doi:10.1038/s41598-021-97539-2 · Cited by 7
Drug susceptibility testing of circulating lung cancer cells for personalized treatment
Balakrishnan, A., Thottian, A. G. F., Babu, K. G., & Kumar, P. (2022) · Medical Oncology · doi:10.1007/s12032-022-01860-3 · Cited by 7
Bioinformatics advances for clinical biomarker development
Pritzker, K. P. H., & Pritzker, L. B. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2012.634797 · Cited by 7
Bokacheva, L., Kotedia, K., Reese, M., Ricketts, S., Halliday, J., Le, C. H., Koutcher, J. A., & Carlin, S. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2830 · Cited by 7
Biomarkers of cancer angioprevention for clinical studies
Albini, A. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.600 · Cited by 8
Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy
Frentzas, S., Lum, C., & Chen, T. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89667 · Cited by 7
Reeh, M., Ghadban, T., Uzunoglu, F. G., Nentwich, M. F., Bockhorn, M., Pantel, K., Izbicki, J. R., & Vashist, Y. K. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.219 · Cited by 7
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
Pories, S. E. (2010) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s6511 · Cited by 7
Ex Vivo Behaviour of Human Bone Tumor Endothelial Cells
Infante, T., Cesario, E., Gallo, M., Fazioli, F., Chiara, A. D., Tutucci, C., Apice, G., & de Nigris, F. (2013) · Cancers · doi:10.3390/cancers5020404 · Cited by 6
Zuo, H.-D., & Zhang, X. M. (2018) · World Journal of Radiology · doi:10.4329/wjr.v10.i10.116 · Cited by 6
Addison, C., Ding, K., Seymour, L., Zhao, H., Laurie, S. A., Shepherd, F. A., Goss, G. D., & Bradbury, P. A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.004 · Cited by 6
Update on the use of angiogenesis inhibitors in adult patients with brain tumors.
Reardon, D. A. (2014) · PubMed · Cited by 6
A Critical Review on Ramucirumab in the Treatment of Advanced Urothelial Cancer
Vlachostergios, P. J., Lee, A., Thomas, C., Walsh, R., & Tagawa, S. T. (2017) · Future Oncology · doi:10.2217/fon-2017-0473 · Cited by 6
Patel, V. K., Shirbhate, E., Singh, V. P., Parveen, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266324868250123052818 · Cited by 5
Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350
Simone, G. D. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1558210 · Cited by 5
Jiménez, B. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1074 · Cited by 5
Hypertension induced by antiangiogenic therapy: clinical and pathophysiological aspects
van den Meiracker, A. H., Lankhorst, S., van Esch, J. H., Danser, A. J., & Kappers, M. H. W. (2012) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2012-000094 · Cited by 5
Precision therapy in advanced urothelial cancer
Schiff, J. P., Barata, P. C., Yu, E. Y., & Grivas, P. D. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1582298 · Cited by 5
Deyell, R. J., Wu, B. H., Rassekh, S. R., Tu, D., Samson, Y., Fleming, A. J., Bouffet, É., Sun, X., Powers, J., Seymour, L., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27540 · Cited by 5
Vail, D. M., Thamm, D. H., & Liptak, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-59496-7.00001-3 · Cited by 6
Yang, W., Li, W., Pan, F., Yang, X., Zhao, X., Li, Q., & Pan, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.11320 · Cited by 5
Chiorean, E. G., Perkins, S. M., Strother, R. M., Younger, A., Funke, J. M., Shahda, S., Hahn, N. M., Sandrasegaran, K., Jones, D. R., Skaar, T. C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0277 · Cited by 5
Imagerie de la perfusion tissulaire et de la perméabilité
Cuénod, C. A., & Balvay, D. (2013) · Journal de radiologie diagnostique et interventionnelle · doi:10.1016/j.jradio.2013.08.011 · Cited by 5
Factores pronósticos e imagen funcional del cáncer de recto
Figueiras, R. G., Domínguez, P. C., Dorrego, R. G., Martin, A., & Gómez‐Caamaño, A. (2011) · Radiología · doi:10.1016/j.rx.2011.05.017 · Cited by 5
Prognostic factors and functional imaging in rectal cancer
Figueiras, R. G., Domínguez, P. C., Dorrego, R. G., Martin, A., & Caamaño, A. G. (2012) · Radiología (English Edition) · doi:10.1016/j.rxeng.2012.05.004 · Cited by 5
Epigenetic modulation of BARD1 to enhance anti-VEGF therapy
Bayraktar, E., Rodriguez‐Aguayo, C., Stur, E., Kumar, S., Mangala, L. S., Jennings, N. B., Bayram, N. N., Corvigno, S., Asare, A., Ivan, C., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102329 · Cited by 4
Antiangiogenic therapies: is VEGF-A inhibition alone enough?
Gordon, M. S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.5 · Cited by 4
Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors
Elgawish, M. S., & Abdeldayem, E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00017-6 · Cited by 4
Reece-Smith, A. M., Parsons, S. L., & Watson, S. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_8 · Cited by 4
Vascular Targeting Approaches to Treat Cancer
Wragg, J. W., & Bicknell, R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7876-8_3 · Cited by 4
Delord, J., Tourani, J. M., Lefresne, F., Pétain, A., Pouget, J.-C., & Ravaud, A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2051-3 · Cited by 4
Yen, C., & Yen, C.-J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.1995353 · Cited by 4
Sonoda, K. (2012) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.22 · Cited by 4
Kwon, I., Wang, R., Prakash, N., Bozard, B. R., Baudino, T. A., Liu, K., Thangaraju, M., Dong, Z., & Browning, D. D. (2011) · Cancer · doi:10.1002/cncr.26192 · Cited by 4
Antigen detection using fluorophore-modified antibodies and magnetic microparticles
Zhang, W., & Serpe, M. J. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.07.070 · Cited by 4
The hypertensive effect of sorafenib is abolished by sildenafil
Dabiré, H., Dramé, F., Cita, N., & Ghaleh, B. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-00064-w · Cited by 4
Kazimova, T., Tschanz, F., Sharma, A., Telarović, I., Wachtel, M., Pedot, G., Schäfer, B. W., & Pruschy, M. N. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0403 · Cited by 4
Tsang, E. S., Aggarwal, R. R., Bergsland, E. K., Calabrese, S., Rozié, A., Chaudhuri, S., Dhawan, M. S., Pawłowska, N., Grabowsky, J. A., Thomas, S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00328 · Cited by 3
Pietrantonio, F., Biondani, P., Pellegrinelli, A., Marchianò, A. V., Dotti, K. F., Buzzoni, R., & Bartolomeo, M. D. (2012) · Medical Oncology · doi:10.1007/s12032-011-0132-5 · Cited by 3
Spring, B. Q., Palanisami, A., Zheng, L., Blatt, A. E., Sears, R. B., & Hasan, T. G. (2013) · Journal of Biomedical Optics · doi:10.1117/1.jbo.18.9.096015 · Cited by 3
Fronczyk, K. M., Guindani, M., Hobbs, B. P., Ng, C. S., & Vannucci, M. (2015) · Cancer Informatics · doi:10.4137/cin.s31933 · Cited by 3
Lacal, P. M., Atzori, M. G., Ruffini, F., Tentori, L., & Graziani, G. (2018) · Oncology Reports · doi:10.3892/or.2018.6291 · Cited by 3
Zhang, W., Yao, J., Zhong, M., Zhang, Y., Guo, X., & Wang, H. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2021-0077-ra · Cited by 3
Systemic Treatment: Maintenance Compared with Holiday
Punt, C. J. A., Simkens, L. H. J., & Koopman, M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.85 · Cited by 3
Modes of Neovascularization in Tumors and Clinical Translation of Antiangiogenic Therapy
Jain, R. K., Fukumura, D., & Duda, D. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05502-7 · Cited by 3
Self-citationPancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistance
Zheng, Y., Sun, H., Fu, Z., Chen, H., Cai, G., Huang, X., Pan, Y., Yu, K., Chen, P., Liang, Z., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.06.022 · Cited by 2
Models for Evaluation of Targeted Therapies of Invasive and Metastatic Disease
Eccles, S. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-968-0_19 · Cited by 2
Tumor growth fueled by spurious senescence phenotypes
Mastri, M., & Ebos, J. M. L. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1575707 · Cited by 2
Mathematical and Computational Models in Cancer
Chowbina, S., Janes, K. A., Peirce, S. M., & Papin, J. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-60761-478-4_6 · Cited by 2
New Therapies and Functional-Molecular Imaging
García‐Figueiras, R., & Padhani, A. R. (2013) · Springer eBooks · doi:10.1007/978-3-642-40412-2_5 · Cited by 2
Therapeutic Implications of Angiogenesis in Cancer
Makhoul, I., Atrash, S., Arnaoutakis, K., Safar, M., Pennisi, A., Huffman, L. B., & Griffin, R. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-61115-0_9 · Cited by 2
Angiogenesis and Neurogenesis After Ischemic Stroke
Li, W., & Wang, Y. (2017) · Translational medicine research · doi:10.1007/978-981-10-5804-2_14 · Cited by 2
Response to anti-angiogenesis: An ever changing feature
Bertolini, F. (2011) · The Breast · doi:10.1016/s0960-9776(11)70296-x · Cited by 2
Apports récents de la pharmacogénomique dans le traitement des cancers colorectaux
Astier, A. (2010) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2010.04.001 · Cited by 2
Yang, X., Mrózek, E., Lustberg, M. B., Jia, G., Sammet, S., Sammet, C. L., Shapiro, C. L., & Knopp, M. V. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.04.026 · Cited by 2
Verstraete, M., Debucquoy, A., Sagaert, X., Cutsem, E. V., & Karin, H. (2013) · Advances in Cancer Research & Treatment · doi:10.5171/2012.796042 · Cited by 2
Multimodality Imaging of Angiogenesis
Lee, H., & Jeong, J.-M. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010166 · Cited by 2
Mechanistic insights into the heterogeneous response to anti‐VEGF treatment in tumors
Ding, L., & Finley, S. D. (2021) · Computational and Systems Oncology · doi:10.1002/cso2.1013 · Cited by 2
Jackson, A., & O’Connor, J. P. B. (2013) · Springer eBooks · doi:10.1007/978-3-642-40412-2_7 · Cited by 2
Fu, S., Li, L., Li, X., Wu, Q., Wang, X., Huang, Y., Hu, H., & Cao, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.888106 · Cited by 2
The Present and Future of Optical Imaging Technologies in the Clinic: Diagnosis and Therapy
Stater, E. P., Skubal, M., Tamura, R., & Grimm, J. (2019) · Topics in medicinal chemistry · doi:10.1007/7355_2019_84 · Cited by 2
Biomarkers of angiogenesis and their role in clinical oncology
Pircher, A., Heidegger, I. M., Gunsilius, E., & Hilbe, W. (2010) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-010-0181-z · Cited by 2
Lindauer, A. (2011) · bonndoc (University of Bonn) · Cited by 2
Shi, L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc271 · Cited by 2
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
An endothelial cell competition assay for determinants of the response to targeted anti-angiogenics
Halford, M. M., He, M. Y., Amin, N., Paquet‐Fifield, S., Achen, M. G., Vincan, E., & Stacker, S. A. (2025) · Growth Factors · doi:10.1080/08977194.2025.2516463 · Cited by 1
Evolving treatment strategies in meningioma: from traditional approaches to emerging therapies
Patel, T. D., Henna, F., Ibrahim, H. Y., Maloth, A. K., Rehman, A. U., Kazmi, S. R. Z., Hussain, A., & Hanani, C. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003556 · Cited by 1
Tumor Microcirculation: Abnormalities and Normalization
Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1
Lei, L., Yang, H., Du, M., & Chen, Y. (2026) · BIO Integration · doi:10.15212/bioi-2025-0117 · Cited by 1
Raimbourg, J., Abdelghani, M. B., Boige, V., Botsen, D., Carnot, A., Coutzac, C., Delaye, M., Carvalho, N. D. S., Santos, M. D., Edeline, J., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103177 · Cited by 1
Metronomic Chemotherapy in Pediatric Malignancies
Baluch, N., Kumar, S., Mokhtari, R., & Baruchel, S. (2014) · Springer eBooks · doi:10.1007/978-3-662-43604-2_11 · Cited by 1
Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan
Hasselbalch, B., Lassen, U., & Poulsen, H. S. (2011) · Springer eBooks · doi:10.1007/978-94-007-0618-7_30 · Cited by 1
Broom, R. J., Caldwell, I. R., Hanning, F. J., Fong, P. C. C., Deva, S., & Oei, P. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.01.008 · Cited by 1
Najjar, F., Al-Massarani, G., Banat, I., & Alammar, M. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000154 · Cited by 1
Statistical Issues in the Design and Planning of Proteomic Profiling Experiments
Cairns, D. A. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1872-0_13 · Cited by 1
Metadata
- Authors
- Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G.
- Affiliations
- Harvard University (US)
- Duke Medical Center (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-06
- Volume
- 6
- Issue
- 6
- Pages
- 327-338
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- PMC
- PMC3057433
- OpenAlex
- W1993016882
- Cited by
- 572
- References
- 83
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 9 · 2023: 15 · 2022: 11 · 2021: 19 · 2020: 26 · 2019: 17 · 2018: 25 · 2017: 33 · 2016: 35 · 2015: 38 · 2014: 44 · 2013: 57 · 2012: 67
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA115767, R01CA57683, R01 CA 85140, R21CA117079, R01CA085140, R01CA057683, R21-CA 99237, P01CA080124, R21CA099237, R01CA126642, K24CA125440, R01CA129371, P01-CA-80124)
- National Center for Research Resources (P41-RR-14075, M01RR001066, P41RR014075, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- anti-angiogenic therapy, biomarkers, treatment response, drug resistance, patient selection, VEGF polymorphisms, type IV collagen, pharmacodynamic biomarkers, imaging biomarkers, Ktrans, placental growth factor, stromal cell-derived factor-1α, interleukin-6, tumor stroma
- MeSH terms
- Humans, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Drug Resistance, Neoplasm, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
